NasdaqGS - Nasdaq Real Time Price USD

GRAIL, Inc. (GRAL)

Compare

17.73

+0.07

+(0.40%)

At close: January 10 at 4:00:02 PM EST

18.10

+0.37

+(2.09%)

After hours: January 10 at 5:24:06 PM EST

Disappointing week for GRAIL, Inc. (NASDAQ:GRAL) institutional investors who control 48% of the company

Key Insights Significantly high institutional ownership implies GRAIL's stock price is sensitive to their trading...

Simply Wall St. 18 days ago

GRAL
+0.40%
GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15 at 9:00 a.m. PT.

PR Newswire 25 days ago

GRAL
+0.40%
What's Going On With Illumina Stock On Monday?

On Friday, Nasdaq Inc’s (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on December 23. Illumina, Inc. (NASDAQ:ILMN) was removed from the index. Year to date, the stock has increased around 8%, underperforming iShares Core S&P Mid-Cap ETF (NYSE:IJH). The provider of DNA sequencing and array-based technologies has been in the news due to its controversial multi-billion dollar deal to acquire cancer test maker Grail Inc (NASDAQ:GRAL). Also

Benzinga 27 days ago

ILMN
-2.14%
GRAL
+0.40%
One Of IBD's Best Screens Identifies These Four Market Leaders, Including Garmin, Ollie's

Garmin stock, along with Ollie's Bargain Outlet, are among the best stocks to watch on the stock market today.

Investor's Business Daily last month

GRMN

AOSL

OLLI
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 115,093 shares of GRAIL's common stock to 46 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form

PR Newswire last month

GRAL
+0.40%
Grail 1st-Mover Advantage Faces Regulatory Hurdles in Multi-Cancer Detection, Morgan Stanley Says

Grail's (GRAL) innovative approach positions its as a first-mover in the $100 billion total addressa

PREMIUM
MT Newswires last month

GRAL
+0.40%
GRAIL to Participate in Upcoming Investor Conferences

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will participate in the following investor conferences.

PR Newswire last month

GRAL
+0.40%
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca (LSE/STO/Nasdaq:AZN) in collaboration with Daiichi Sankyo (TSE: 4568).

PR Newswire last month

DSKYF

DSNKY

GRAL
+0.40%
Is Illumina, Inc. (ILMN) the Best Immunotherapy Stock to Buy Now?

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by […]

Insider Monkey last month

ILMN
-2.14%
GRAL
+0.40%
GRAIL Inc (GRAL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...

GRAIL Inc (GRAL) reports a 38% revenue increase and outlines strategic plans for future growth and cost efficiency.

GuruFocus.com last month

GRAL
+0.40%
GRAIL Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

GRAIL ( NASDAQ:GRAL ) Third Quarter 2024 Results Key Financial Results Net loss: US$125.7m (flat on 3Q 2023). US$3.94...

Simply Wall St. last month

GRAL
+0.40%
GRAIL Reports Third Quarter 2024 Financial Results

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter 2024.

PR Newswire last month

GRAL
+0.40%
GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, Nov. 21 at 11:00 a.m. ET.

PR Newswire 2 months ago

GRAL
+0.40%
GRAIL to Announce Third Quarter 2024 Financial Results

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2024 following the close of market on Tuesday, Nov. 12, 2024. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.

PR Newswire 2 months ago

GRAL
+0.40%
GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced early results from the REFLECTION study, which aims to understand the real-world experience of the Galleri® multi-cancer early detection (MCED) test in routine clinical settings. The Galleri test is recommended for adults with an elevated risk for cancer, such as those age 50 or older. In this study, a diverse population of veterans from U.S. Department of Veterans Affai

PR Newswire 2 months ago

GRAL
+0.40%
GRAIL Appoints Sarah Krevans to Board of Directors

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent.

PR Newswire 2 months ago

GRAL
+0.40%
GRAIL, Inc. (GRAL): Jeff Bezos Is Buying This Stock Now

We recently compiled a list of the 8 Stocks Jeff Bezos is Buying. In this article, we are going to take a look at where GRAIL, Inc. (NASDAQ:GRAL) stands against the other stocks Jeff Bezos is buying. ‘We are Famously Unprofitable’ Jeff Bezos is a name closely tied to Amazon the company he reportedly founded in […]

Insider Monkey 2 months ago

GRAL
+0.40%
We're Keeping An Eye On GRAIL's (NASDAQ:GRAL) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 3 months ago

GRAL
+0.40%
Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology

GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings of the performance of its Galleri® multi-cancer early detection (MCED) test in prostate cancer were published in JCO Precision Oncology. The data support the clinical performance of the Galleri test to preferentially screen for aggressive, clinically significant prostate cancer as compared to slow-growing (indolent) cases in the Circulating Cell-fre

PR Newswire 4 months ago

GRAL
+0.40%
ILMN
-2.14%
GRAIL to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 3:20 p.m. ET on Sept. 4, 2024.

PR Newswire 4 months ago

GRAL
+0.40%

Performance Overview

Return	GRAL	S&P 500
YTD	-4.88%	-1.35%
1-Year	+27.10%	+22.51%
3-Year	+27.10%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GRAIL, Inc. (GRAL)

Disappointing week for GRAIL, Inc. (NASDAQ:GRAL) institutional investors who control 48% of the company

GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference

What's Going On With Illumina Stock On Monday?

One Of IBD's Best Screens Identifies These Four Market Leaders, Including Garmin, Ollie's

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Grail 1st-Mover Advantage Faces Regulatory Hurdles in Multi-Cancer Detection, Morgan Stanley Says

GRAIL to Participate in Upcoming Investor Conferences

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

Is Illumina, Inc. (ILMN) the Best Immunotherapy Stock to Buy Now?

GRAIL Inc (GRAL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...

GRAIL Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

GRAIL Reports Third Quarter 2024 Financial Results

GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

GRAIL to Announce Third Quarter 2024 Financial Results

GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference

GRAIL Appoints Sarah Krevans to Board of Directors

GRAIL, Inc. (GRAL): Jeff Bezos Is Buying This Stock Now

We're Keeping An Eye On GRAIL's (NASDAQ:GRAL) Cash Burn Rate

Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology

GRAIL to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Performance Overview